Relay Therapeutics, Inc. RLAY Enterprise value

Enterprise value at other companies

SchrodingerSDGR

$1.03B-26.2%

PVL

Palvella TherapeuticsPVLA

$1.58B—

Recursion Pharmaceuticals, Inc.RXRX

$1.47B-13.4%

CelcuityCELC

$5.51B+1,086%

Revolution Medicines, Inc.RVMD

$39.15B+445%

Ligand PharmaceuticalsLGND

$6.46B+191%

FAQ

What is Relay Therapeutics, Inc.'s enterprise value?

Relay Therapeutics, Inc. (RLAY) reported enterprise value of $3.99B in Q2 2026.

How has Relay Therapeutics, Inc.'s enterprise value changed year-over-year?

Relay Therapeutics, Inc.'s enterprise value increased by 717.5% year-over-year, from $487.72M to $3.99B.

What is the long-term trend for Relay Therapeutics, Inc.'s enterprise value?

Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s enterprise value has grown at a -15.7% compound annual growth rate (CAGR), from $3.33B to $1.41B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.